Pfizer (NYSE:PFE) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Pfizer (NYSE:PFE) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $45.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an equal weight rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a moderate buy rating to a strong-buy rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a neutral rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, Daiwa Capital Markets upgraded Pfizer from a neutral rating to an outperform rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of Moderate Buy and an average price target of $34.54.

Pfizer Stock Down 0.3 %

Shares of NYSE:PFE opened at $29.67 on Monday. The stock’s 50-day moving average is $29.35 and its 200 day moving average is $28.20. The company has a market cap of $168.13 billion, a PE ratio of -494.42, a P/E/G ratio of 1.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer has a 1 year low of $25.20 and a 1 year high of $34.11.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. Sell-side analysts anticipate that Pfizer will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.66%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Hedge Funds Weigh In On Pfizer

Several large investors have recently modified their holdings of PFE. Olistico Wealth LLC bought a new position in shares of Pfizer in the second quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP bought a new position in Pfizer in the 2nd quarter valued at approximately $31,000. Creekmur Asset Management LLC purchased a new stake in Pfizer during the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC increased its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.